Cargando…
Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)
Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein inte...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793299/ https://www.ncbi.nlm.nih.gov/pubmed/33417604 http://dx.doi.org/10.1371/journal.pone.0245258 |
_version_ | 1783633958425067520 |
---|---|
author | Egieyeh, Samuel Egieyeh, Elizabeth Malan, Sarel Christofells, Alan Fielding, Burtram |
author_facet | Egieyeh, Samuel Egieyeh, Elizabeth Malan, Sarel Christofells, Alan Fielding, Burtram |
author_sort | Egieyeh, Samuel |
collection | PubMed |
description | Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank that can bind to the SARS-CoV-2 spike protein interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the hACE2 receptor to modulate the protein-protein interaction required for infection by the SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological indications of the peptide drugs predicted as potential inhibitors of the interaction between the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs have been investigated for the treatment of acute respiratory distress syndrome (ARDS), viral infection, inflammation and angioedema, and to stimulate the immune system, and potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits may be used as a basis to design new peptide or peptidomimetic drugs with better affinity and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2 spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus. |
format | Online Article Text |
id | pubmed-7793299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-77932992021-01-27 Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) Egieyeh, Samuel Egieyeh, Elizabeth Malan, Sarel Christofells, Alan Fielding, Burtram PLoS One Research Article Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank that can bind to the SARS-CoV-2 spike protein interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the hACE2 receptor to modulate the protein-protein interaction required for infection by the SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological indications of the peptide drugs predicted as potential inhibitors of the interaction between the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs have been investigated for the treatment of acute respiratory distress syndrome (ARDS), viral infection, inflammation and angioedema, and to stimulate the immune system, and potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits may be used as a basis to design new peptide or peptidomimetic drugs with better affinity and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2 spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus. Public Library of Science 2021-01-08 /pmc/articles/PMC7793299/ /pubmed/33417604 http://dx.doi.org/10.1371/journal.pone.0245258 Text en © 2021 Egieyeh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Egieyeh, Samuel Egieyeh, Elizabeth Malan, Sarel Christofells, Alan Fielding, Burtram Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title_full | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title_fullStr | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title_full_unstemmed | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title_short | Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) |
title_sort | computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of sars-cov-2 spike protein with its target (humanace2) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793299/ https://www.ncbi.nlm.nih.gov/pubmed/33417604 http://dx.doi.org/10.1371/journal.pone.0245258 |
work_keys_str_mv | AT egieyehsamuel computationaldrugrepurposingstrategypredictedpeptidebaseddrugsthatcanpotentiallyinhibittheinteractionofsarscov2spikeproteinwithitstargethumanace2 AT egieyehelizabeth computationaldrugrepurposingstrategypredictedpeptidebaseddrugsthatcanpotentiallyinhibittheinteractionofsarscov2spikeproteinwithitstargethumanace2 AT malansarel computationaldrugrepurposingstrategypredictedpeptidebaseddrugsthatcanpotentiallyinhibittheinteractionofsarscov2spikeproteinwithitstargethumanace2 AT christofellsalan computationaldrugrepurposingstrategypredictedpeptidebaseddrugsthatcanpotentiallyinhibittheinteractionofsarscov2spikeproteinwithitstargethumanace2 AT fieldingburtram computationaldrugrepurposingstrategypredictedpeptidebaseddrugsthatcanpotentiallyinhibittheinteractionofsarscov2spikeproteinwithitstargethumanace2 |